JP2015518819A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518819A5
JP2015518819A5 JP2015511675A JP2015511675A JP2015518819A5 JP 2015518819 A5 JP2015518819 A5 JP 2015518819A5 JP 2015511675 A JP2015511675 A JP 2015511675A JP 2015511675 A JP2015511675 A JP 2015511675A JP 2015518819 A5 JP2015518819 A5 JP 2015518819A5
Authority
JP
Japan
Prior art keywords
viral protein
protein complex
animal
viral
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518819A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/040228 external-priority patent/WO2013169961A1/en
Publication of JP2015518819A publication Critical patent/JP2015518819A/ja
Publication of JP2015518819A5 publication Critical patent/JP2015518819A5/ja
Pending legal-status Critical Current

Links

JP2015511675A 2012-05-09 2013-05-09 立体構造的に特異的なウイルス免疫原 Pending JP2015518819A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644830P 2012-05-09 2012-05-09
US61/644,830 2012-05-09
PCT/US2013/040228 WO2013169961A1 (en) 2012-05-09 2013-05-09 Conformationally specific viral immunogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018088600A Division JP6692853B2 (ja) 2012-05-09 2018-05-02 立体構造的に特異的なウイルス免疫原

Publications (2)

Publication Number Publication Date
JP2015518819A JP2015518819A (ja) 2015-07-06
JP2015518819A5 true JP2015518819A5 (enExample) 2016-06-30

Family

ID=49548782

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015511675A Pending JP2015518819A (ja) 2012-05-09 2013-05-09 立体構造的に特異的なウイルス免疫原
JP2018088600A Expired - Fee Related JP6692853B2 (ja) 2012-05-09 2018-05-02 立体構造的に特異的なウイルス免疫原
JP2020073065A Pending JP2020125323A (ja) 2012-05-09 2020-04-15 立体構造的に特異的なウイルス免疫原
JP2022128985A Active JP7472209B2 (ja) 2012-05-09 2022-08-12 立体構造的に特異的なウイルス免疫原

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018088600A Expired - Fee Related JP6692853B2 (ja) 2012-05-09 2018-05-02 立体構造的に特異的なウイルス免疫原
JP2020073065A Pending JP2020125323A (ja) 2012-05-09 2020-04-15 立体構造的に特異的なウイルス免疫原
JP2022128985A Active JP7472209B2 (ja) 2012-05-09 2022-08-12 立体構造的に特異的なウイルス免疫原

Country Status (7)

Country Link
US (6) US20130302366A1 (enExample)
EP (2) EP3483174A1 (enExample)
JP (4) JP2015518819A (enExample)
AU (5) AU2013259548A1 (enExample)
CA (1) CA2873048C (enExample)
IN (1) IN2014DN09445A (enExample)
WO (1) WO2013169961A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6685903B2 (ja) * 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質
WO2015020913A2 (en) 2013-08-03 2015-02-12 Marshall Christopher Patrick Influenza hemagglutinin proteins and methods of thereof
EP3664836A4 (en) 2017-08-07 2021-05-19 Calder Biosciences Inc. PRE-FUSION RSV PRE-FUSION STABILIZED IN TERMS OF CONFORMITY
US11623004B2 (en) 2018-03-16 2023-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncytial virus infection
MX2022014224A (es) * 2020-05-12 2023-02-23 Univ California Construcciones de anticuerpos de dominio individual neutralizantes contra sars-cov2.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311920B1 (en) * 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US6534064B1 (en) 1999-10-13 2003-03-18 Chiron Corporation Stabilized protein particles for inducing cellular immune responses
ATE513056T1 (de) 1999-10-15 2011-07-15 Avatar Medical L L C Stabilisierte proteine
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7179468B1 (en) * 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
WO2003052122A2 (en) 2001-12-17 2003-06-26 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Gp41 inhibitor
US20080206264A1 (en) 2003-02-04 2008-08-28 New York University Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists
EP1641813B1 (en) * 2003-07-03 2011-11-09 Avatar Biotechnologies, Inc. Methods for obtaining molecules with reduced immunogenicity
JP5069558B2 (ja) * 2004-06-01 2012-11-07 メルク・シャープ・エンド・ドーム・コーポレイション ＨＩＶｇｐ４１融合中間物質の安定したペプチド模倣薬
CA2655934A1 (en) * 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Soluble stabilized trimeric hiv env proteins and uses thereof
KR101351195B1 (ko) * 2007-07-27 2014-01-14 이매틱스 바이오테크놀로지스 게엠베하 면역 치료를 위한 새로운 면역원성 에피톱
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
WO2009048631A1 (en) * 2007-10-11 2009-04-16 University Of Tennessee Research Foundation PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF
SMT202000101T1 (it) * 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
WO2011066221A1 (en) 2009-11-24 2011-06-03 International Aids Vaccine Initiative Immunogen prioritization for vaccine design
US20130236905A1 (en) 2010-05-18 2013-09-12 Christopher Marshall Assay for identifying antigens that activate b cell receptors comprising neutralizing antibodies
US20130149336A1 (en) * 2011-10-27 2013-06-13 Brian L. Hjelle Methods for Screening Viral Like Particles and Identifying Neutralizing Epitopes and Related Vaccines, Constructs, and Libraries
WO2013107290A1 (en) 2012-01-20 2013-07-25 The Government of the Hong Kong Special Administrative Region of the People's Republic of China A novel paramyxovirus and uses thereof

Similar Documents

Publication Publication Date Title
JP6957580B2 (ja) 新規多価ナノ粒子に基づくワクチン
Khurana et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets
Allen et al. Next generation methodology for updating HA vaccines against emerging human seasonal influenza A (H3N2) viruses
Buonaguro et al. Developments in virus-like particle-based vaccines for infectious diseases and cancer
MX375379B (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
JP2015518819A5 (enExample)
Fontana et al. Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
JP2020125323A5 (enExample)
JP2014530010A5 (enExample)
Tan et al. Recent advancements in combination subunit vaccine development
JP2017035093A5 (enExample)
Wu et al. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus
JP2014237714A5 (enExample)
JP2015524422A5 (enExample)
JP2012501959A5 (enExample)
Verma et al. Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies
MY180109A (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
Castro et al. Computational design of vaccine immunogens
JP2013523783A5 (enExample)
Huang et al. N-linked glycans and K147 residue on hemagglutinin synergize to elicit broadly reactive H1N1 influenza virus antibodies
Brinkkemper et al. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses
Khurana et al. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine
McCraw et al. Characterization of influenza vaccine hemagglutinin complexes by cryo-electron microscopy and image analyses reveals structural polymorphisms
Sigoillot-Claude et al. A versatile in vitro ELISA test for quantification and quality testing of infectious, inactivated and formulated rabies virus used in veterinary monovalent or combination vaccine